Sureseal

País: Nova Zelândia

Língua: inglês

Origem: Ministry for Primary Industries

Ingredientes ativos:

bismuth subnitrate

Disponível em:

Norbrook NZ Limited

DCI (Denominação Comum Internacional):

bismuth subnitrate

Composição:

bismuth subnitrate 650 g/kg

Área terapêutica:

Antimicrobial

Status de autorização:

ACVM Registered

Data de autorização:

2013-02-27

Características técnicas

Sureseal (A10866)
June 2019
Page 1 of 7
Syringe label
_ _
FOR ANIMAL TREATMENT ONLY RESTRICTED VETERINARY MEDICINE SURESEAL
READ CARTON LABEL BEFORE USE
Contents 4.0 g
ACTIVE INGREDIENT:
BISMUTH SUBNITRATE 650 mg/g
INDICATIONS:
For the prevention of mastitis during the non-lactating (dry) period.
DOSAGE & ADMINISTRATION:
For intramammary use at drying off only. Taking antiseptic
precautions, introduce contents of one syringe into each
udder quarter immediately after the last milking of the lactation (at
drying off).
CONTRA-INDICATIONS:
Do not use in lactating cows.
Do not use in cows with clinical mastitis.
WITHHOLDING PERIODS:
MILK: Milk intended for sale for human consumption must be discarded
during treatment for
not less than 8 milkings or approximately 96 hours after calving.
MEAT: Nil
Store below 25
°
C. Protect from light.
KEEP OUT OF REACH OF CHILDREN.
ACVM No. A10866
See www.foodsafety.govt.nz for registration conditions.
Registered to and Distributed by:
Norbrook NZ Ltd
KPMG Centre, 18 Viaduct Harbour Avenue
Auckland
Ph: 0800 224 022
Batch:
Expiry:
Sureseal (A10866)
June 2019
Page 2 of 7
Carton label
FOR ANIMAL TREATMENT ONLY RESTRICTED VETERINARY MEDICINE SURESEAL
For the prevention of mastitis during the non-lactating (dry) period
READ THE ENTIRE LABEL BEFORE USE
PRESENTATION:
SURESEAL is a sterile intramammary suspension. Each syringe contains
4.0 g of suspension incorporating 2.6gm
of Bismuth subnitrate. Supplied in outers of 24, 60, 100 and 120
unit-dose syringes.
INDICATIONS:
SURESEAL is indicated for the prevention of mastitis during the
non-lactating (dry) period:
•
in lactating heifers (first calves) and cows with somatic cell counts
(SCC) of less than 120,000 and 150,000
respectively.
•
in cows and heifers with a higher somatic cell counts (SCC), or
immediately following treatment with
Noroclox DC 600 (A9281), Cloxamp DC 500 (A8038), Cloxamp DC 600
(A8039) or Durodry (A7862). Refer
also to the labels for these products.
Sureseal is also indicated for the prevention of peri-calving mastiti